Literature DB >> 8891111

Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay.

J R Mascola1, M K Louder, S R Surman, T C Vancott, X F Yu, J Bradac, K R Porter, K E Nelson, M Girard, J G McNeil, F E McCutchan, D L Birx, D S Burke.   

Abstract

Classification of human immunodeficiency virus type 1 (HIV-1) by neutralization serotype may be important for the design of active and passive immunization strategies. Neutralizing antibody serotyping is hindered by the lack of standard reagents and assay format, and by the weak activity of many individual sera. To facilitate cross-clade neutralization analysis, we used an infectivity reduction assay (IRA) and selected clade-specific serum (or plasma) pools from subjects infected with clade B and E HIV-1, respectively. Several serum pools were utilized; some were selected for strong neutralizing activity against intraclade viruses and others were derived from conveniently available samples. Against a panel of 51 clade B and E viruses, serum pools displayed strong neutralization of most intraclade viruses and significantly diminished cross-clade neutralization. Results were confirmed against a blinded panel of 20 viruses. The data indicate that the phylogenetic classification of virus subtypes B and E corresponds to two distinct neutralization serotypes. This approach to neutralizing antibody serotyping may be useful in defining the antigenic relationship among viruses from other clades.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891111     DOI: 10.1089/aid.1996.12.1319

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  28 in total

Review 1.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.

Authors:  Peng Fei Zhang; Peter Bouma; Eun Ju Park; Joseph B Margolick; James E Robinson; Susan Zolla-Pazner; Michael N Flora; Gerald V Quinnan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China.

Authors:  Hong Shang; Xiaoxu Han; Xuanling Shi; Teng Zuo; Mark Goldin; Dan Chen; Bing Han; Wei Sun; Hao Wu; Xinquan Wang; Linqi Zhang
Journal:  J Biol Chem       Date:  2011-02-16       Impact factor: 5.157

4.  Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells.

Authors:  Anna Smed-Sörensen; Karin Loré; Jayanand Vasudevan; Mark K Louder; Jan Andersson; John R Mascola; Anna-Lena Spetz; Richard A Koup
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.

Authors:  Peter Hraber; Bette T Korber; Alan S Lapedes; Robert T Bailer; Michael S Seaman; Hongmei Gao; Kelli M Greene; Francine McCutchan; Carolyn Williamson; Jerome H Kim; Sodsai Tovanabutra; Beatrice H Hahn; Ronald Swanstrom; Michael M Thomson; Feng Gao; Linda Harris; Elena Giorgi; Nicholas Hengartner; Tanmoy Bhattacharya; John R Mascola; David C Montefiori
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

6.  Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

Authors:  S L Buge; L Murty; K Arora; V S Kalyanaraman; P D Markham; E S Richardson; K Aldrich; L J Patterson; C J Miller; S M Cheng; M Robert-Guroff
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

7.  A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1.

Authors:  F Gao; D L Robertson; C D Carruthers; S G Morrison; B Jian; Y Chen; F Barré-Sinoussi; M Girard; A Srinivasan; A G Abimiku; G M Shaw; P M Sharp; B H Hahn
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity.

Authors:  Nobuyuki Matoba; Adam S Husk; Brian W Barnett; Michelle M Pickel; Charles J Arntzen; David C Montefiori; Atsushi Takahashi; Kazunobu Tanno; Satoshi Omura; Huyen Cao; Jason P Mooney; Carl V Hanson; Haruo Tanaka
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

9.  Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.

Authors:  Nicole A Doria-Rose; Rachel M Klein; Marcus G Daniels; Sijy O'Dell; Martha Nason; Alan Lapedes; Tanmoy Bhattacharya; Stephen A Migueles; Richard T Wyatt; Bette T Korber; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

10.  Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection.

Authors:  Melody G Duvall; Karin Loré; Hetty Blaak; David A Ambrozak; William C Adams; Kathlyn Santos; Christof Geldmacher; John R Mascola; Andrew J McMichael; Assan Jaye; Hilton C Whittle; Sarah L Rowland-Jones; Richard A Koup
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.